We show that genetic ablation of endothelial Twist1, as well as pharmacological inhibition of Twist1, reduces Mφ-mediated tumor immunosuppression and circumvents tumor resistance to CAR T cell immunotherapy. This evidence concerns the gene TWIST1 and neoplasm.